2013
DOI: 10.3899/jrheum.120725
|View full text |Cite
|
Sign up to set email alerts
|

Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis

Abstract: Objective.Biomarkers of progression of interstitial lung disease (ILD) are needed to allow early therapeutic intervention in patients with scleroderma-associated disease (SSc-ILD).Methods.A panel of 8 serum cytokines [interleukin 6 (IL-6), IL-8, IL-10, CCL2, CXCL10, vascular endothelial growth factor, fibroblast growth factor 2, and CX3CL1] was assessed by Luminex bead technology in exploratory cohorts of 74 patients with SSc and 58 patients with idiopathic pulmonary fibrosis (IPF). Mortality and significant l… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
144
0
2

Year Published

2015
2015
2023
2023

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 223 publications
(150 citation statements)
references
References 43 publications
4
144
0
2
Order By: Relevance
“…Interestingly, it has been suggested that altered IL-6 signalling in IPF primary fibroblast culture may enhance the resistance of these cells to apoptosis and contribute to a pro-fibrotic effect of IL-6 in IPF [27]. In addition, IL-6 serum levels are suggested to be predictive of early disease progression in patients with systemic sclerosis-associated interstitial lung disease [28].…”
Section: Impaired Activation Of the Nlrp3 Inflammasome In Ipfmentioning
confidence: 99%
“…Interestingly, it has been suggested that altered IL-6 signalling in IPF primary fibroblast culture may enhance the resistance of these cells to apoptosis and contribute to a pro-fibrotic effect of IL-6 in IPF [27]. In addition, IL-6 serum levels are suggested to be predictive of early disease progression in patients with systemic sclerosis-associated interstitial lung disease [28].…”
Section: Impaired Activation Of the Nlrp3 Inflammasome In Ipfmentioning
confidence: 99%
“…Experimental data demonstrated that treatment with anti-topoisomerase I antibody induces skin and lung fibrosis stimulating IL-6 production [108]. Moreover, IL-6 is an independent predictor of decline in diffusing capacity of the lung for carbon monoxide (DLCO), in both IPF and SSc-ILD patients [109]. Oncostatin M, an IL-6 family cytokine, has been implicated in a number of biological processes, including the modulation of ECM and the induction of pulmonary inflammation and fibrosis, both in SSc-ILD and IPF [110], through an IL-4/IL-13 and TGF-β-independent mechanism.…”
Section: Polymorphonuclear Cell Activitymentioning
confidence: 99%
“…Recently, a loss of density on capillaroscopy was shown to be associated with worse FVC and DLCO [40] and biomarkers that correlate with the severity of fibrosis have been proposed: elevated levels of chitinase [41], tenascin C [42], growth differentiation protein 15 [43], cartilage oligomeric matrix protein, alveolar epithelial cell antigen, KL-6 [44] and the chemokine CXCL4 [45]. Serum IL-6 predicted early disease progression and IL-6 values >767 pg·mL −1 were predictive of risk of death within the first 30 months in patients with mild SSc-ILD [46].…”
Section: The Outcome and Its Predictorsmentioning
confidence: 99%